RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) — XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), introduced in the present day that it plans to alter the ratio of its American Depositary Shares (“ADSs”) to its extraordinary shares, par worth NIS0.1 per share (the “ADS Ratio”), from the present ADS Ratio of 1 (1) ADS to 1 hundred (100) extraordinary shares, to a brand new ADS Ratio of 1 (1) ADS to 4 hundred (400) extraordinary shares (the “ADS Ratio Change”). The Firm anticipates that the ADS Ratio Change will probably be efficient on March 25, 2026 (the “Effective Date”).
For the Firm’s ADS holders, the change within the ADS Ratio can have the identical impact as a one-for-four reverse ADS cut up. On the Efficient Date, registered holders of firm ADSs held in certificated kind will probably be required on a compulsory foundation to give up their certificated ADSs to the depositary financial institution for cancellation and can obtain one (1) new ADS in trade for each 4 (4) present ADSs then-held. Holders of uncertificated ADSs within the Direct Registration System (“DRS”) and in The Depository Belief Firm (“DTC”) can have their ADSs routinely exchanged and needn’t take any motion. The trade of each 4 present ADSs for one (1) new ADS will happen routinely, with present ADSs being cancelled and new ADSs being issued by the depositary financial institution on the Efficient Date.
XTL’s ADSs will proceed to be traded beneath the ticker image “XTLB” on the Nasdaq Capital Market. No charges will probably be charged to ADS holders, for each certificated or uncertificated ADSs, in reference to the trade of present ADSs for brand new ADSs.
No fractional new ADSs will probably be issued in reference to the change within the ADS Ratio. As an alternative, fractional entitlements to new ADSs will probably be aggregated and bought by the depositary financial institution and the web money proceeds from the sale of the fractional ADS entitlements (after deduction of charges, taxes and bills) will probably be distributed to the relevant ADS holders by the depositary financial institution. The ADS Ratio Change can have no affect on XTL’s underlying extraordinary shares, and no extraordinary shares will probably be issued or cancelled in reference to the ADS Ratio Change.
On account of the change within the ADS Ratio, XTL’s ADS buying and selling value is anticipated to extend proportionally, though the Firm can provide no assurance that the ADS buying and selling value after the ADS Ratio Change will probably be equal to or higher than 4 occasions the buying and selling value per ADS earlier than the change.
More Read
About XTL Biopharmaceuticals Ltd.
XTL is an IP Portfolio firm that holds an IP portfolio together with hCDR1 for Lupus (SLE) and Sjögren’s Syndrome (SS) that the corporate sublicenses. The corporate actively pursues strategic collaborations and acquisitions to broaden its therapeutic portfolio into high-value illness areas.
XTL trades on the Nasdaq Capital Market (NASDAQ: XTLB) and Tel Aviv Inventory Alternate (TASE: XTLB.TA).
More Read
Cautionary Notice Relating to Ahead-Trying Statements
This communication comprises forward-looking statements inside the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended. Any statements contained on this communication that aren’t statements of historic reality could also be deemed forward-looking statements. Phrases corresponding to “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and related expressions are supposed to establish such forward-looking statements. All forward-looking statements contain vital dangers and uncertainties that might trigger precise outcomes to vary materially from these expressed or implied within the forward-looking statements, a lot of that are usually exterior the management of the Firm and are tough to foretell. Examples of such dangers and uncertainties embrace, however aren’t restricted to (i) whether or not to the Firm will be capable of obtain sub-licensing charges referring to its Hcdr1 mental property, (ii) the Firm’s skill to efficiently handle and combine joint ventures, acquisitions of companies, options or applied sciences; (iii) unanticipated working prices, transaction prices and precise or contingent liabilities; (iv) the power to draw and retain certified staff and key personnel; (v) hostile results of elevated competitors on the Firm’s future enterprise; (vi) the Firm’s skill to guard its mental property; and (viii) native, business and normal enterprise and financial circumstances. Extra components that might trigger precise outcomes to vary materially from these expressed or implied within the forward-looking statements could be present in the newest annual report on Type 20-F and present studies on Type 6-Ok filed by the Firm with the Securities and Alternate Fee. The Firm anticipates that subsequent occasions and developments could trigger its plans, intentions and expectations to alter. The Firm assumes no obligation, and it particularly disclaims any intention or obligation, to replace any forward-looking statements, whether or not on account of new info, future occasions or in any other case, besides as expressly required by regulation. Ahead-looking statements converse solely as of the date they’re made and shouldn’t be relied upon as representing the Firm’s plans and expectations as of any subsequent date.
For additional info, please contact:
